Homepage > Company > Media > Pharma News > 2023 > Coherus Acquires Rights From Klinge Biopharma for Eylea Biosimilar Candidate

Coherus Acquires Rights From Klinge Biopharma for Eylea Biosimilar Candidate

Coherus BioSciences has inked a licensing deal with Klinge Biopharma for the exclusive U.S. commercial rights to FYB203, Klinge’s investigational biosimilar of Regeneron’s blockbuster drug Eylea (aflibercept).

FYB203 is currently in a phase 3 study to evaluate its safety and efficacy compared with Eylea in patients with wet age-related macular degeneration.

Under the deal, Klinge will receive an upfront payment of approximately $32.5 million. The transaction is expected to be completed in the first quarter of this year.

Coherus plans on filing a biologics license application to the FDA for the biosimilar candidate later this year and aims to launch the product in 2025.

January 19, 2023

https://www.fdanews.com/

Read also

Chengdu Baiyu enters into a license agreement for the development and commercialization of its Anti-tumor small molecule inhibitor

Chengdu Baiyu Pharmaceutical Co., Ltd. (Chengdu, China) announced that it has entered into an exclusive license agreement with Novartis for a small molecule anti-tumor asset.

Intercept’s liver disease drug Ocaliva faces FDA approval delay

An FDA AdCom in September recommended against full approval for Ocaliva (obeticholic acid) by a 13-1 vote for the treatment of primary biliary cholangitis. The original FDA full approval decis...

Rani Therapeutics shares hold buy rating on positive preclinical data

On Thursday, Rani Therapeutics Holdings Inc. shares maintained a positive outlook as H.C. Wainwright reaffirmed a Buy rating with a $9.00 price target.

Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat

Sagimet Biosciences' Denifanstat shows significant potential in treating MASH, with FDA Breakthrough Therapy designation and peer-reviewed validation, supporting a "Strong Buy" rating. D...